UCB SA of Belgium and Amgen Inc have launched a Phase 3 trial of their jointly developed monoclonal antibody for the treatment of postmenopausal osteoporosis. The antibody binds to and inhibits sclerostin, a protein secreted by bone cells. ---Subscribe to MedNous to access this article--- Company News Research & University News
